Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + GP induction, concurrent chemoradiotherapy, and 1-year sintilimab + capecitabine maintenance for high-risk T4/N3 nasopharyngeal carcinoma
ChiCTR2100051510Phase 2Not yet recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, gemcitabine, cisplatin, nedaplatin and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Jiangmen Central Hospital. Primary endpoint: 3-year overall survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sintilimabgemcitabinecisplatinnedaplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100051510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051510.